Vital Therapies (VTL) versus Its Rivals Head-To-Head Contrast
Vital Therapies (NASDAQ: VTL) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Vital Therapies to similar businesses based on the strength of its valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.
Institutional & Insider Ownership
25.6% of Vital Therapies shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 32.6% of Vital Therapies shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
Vital Therapies has a beta of 5.25, suggesting that its stock price is 425% more volatile than the S&P 500. Comparatively, Vital Therapies’ competitors have a beta of 6.62, suggesting that their average stock price is 562% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Vital Therapies and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vital Therapies Competitors||766||3046||11233||227||2.72|
Vital Therapies currently has a consensus target price of $8.00, indicating a potential upside of 39.13%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.96%. Given Vital Therapies’ higher possible upside, analysts clearly believe Vital Therapies is more favorable than its competitors.
This table compares Vital Therapies and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vital Therapies Competitors||-5,489.22%||-451.65%||-42.63%|
Valuation and Earnings
This table compares Vital Therapies and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Vital Therapies||N/A||-$45.91 million||-4.26|
|Vital Therapies Competitors||$260.16 million||$66.28 million||-6.36|
Vital Therapies’ competitors have higher revenue and earnings than Vital Therapies. Vital Therapies is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Vital Therapies competitors beat Vital Therapies on 8 of the 12 factors compared.
Vital Therapies Company Profile
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.